ImmunoGen (IMGN) : During the past 4 weeks, traders have been relatively bearish on ImmunoGen (IMGN), hence the stock is down -11.46% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.29% relative to the S&P 500. The 4-week change in the price of the stock is -11.58% and the stock has fallen -5.82% in the past 1 week.
The stock has recorded a 20-day Moving Average of 8.61% and the 50-Day Moving Average is 7.9%.The 200 Day SMA reached 62.24%. ImmunoGen, Inc. has dropped 51.33% during the last 3-month period . Year-to-Date the stock performance stands at -79.73%.
ImmunoGen (NASDAQ:IMGN): The stock opened in the green at $2.8 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $2.84 and a low of $2.75 for the day. The stock did not find buyers even at the lows and closed at $2.75 recording a loss of -1.79%. 626,429 shares exchanged hands during the trading day. The stock had closed at $2.8 in the previous days trading.
ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.